Data Insights

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) by Citius Pharmaceuticals for Pseudomonas aeruginosa Infections: Likelihood of Approval

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) is under clinical development by Citius Pharmaceuticals and currently in Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - (Edetate Disodium + Ethyl Alcohol + Minocycline Hydrochloride) in Pseudomonas aeruginosa Infections

Data Insights

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) by Citius Pharmaceuticals for Staphylococcus aureus Infections: Likelihood of Approval

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) is under clinical development by Citius Pharmaceuticals and currently in Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - (Edetate Disodium + Ethyl Alcohol + Minocycline Hydrochloride) in Staphylococcus aureus Infections

Data Insights

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) by Citius Pharmaceuticals for Fungal Infections: Likelihood of Approval

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) is under clinical development by Citius Pharmaceuticals and currently in Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - (Edetate Disodium + Ethyl Alcohol + Minocycline Hydrochloride) in Fungal Infections

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Epithelial Ovarian Cancer: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Epithelial Ovarian Cancer

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Non-Small Cell Lung Cancer

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Endometrial Cancer: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Endometrial Cancer

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Renal Cell Carcinoma: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Renal Cell Carcinoma

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Melanoma: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Melanoma

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Solid Tumor: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Solid Tumor

Data Insights

Denileukin diftitox by Citius Pharmaceuticals for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Pre-Registration for Cutaneous T-Cell Lymphoma. According to GlobalData,...

Data Insights

Risk adjusted net present value: What is the current valuation of Citius Pharmaceuticals's Mino-Lok?

Mino-Lok is a small molecule commercialized by Citius Pharmaceuticals, with a leading Phase III program in Fungal Infections. According to...

Net Present Value Model: Citius Pharmaceuticals Inc's Mino-Lok